Indivior Past Earnings Performance
Past criteria checks 3/6
Indivior's earnings have been declining at an average annual rate of -7.7%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been declining at an average rate of 10.1% per year. Indivior's return on equity is 66.1%, and it has net margins of 18.1%.
Key information
-7.7%
Earnings growth rate
-7.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | -10.1% |
| Return on equity | 66.1% |
| Net Margin | 18.1% |
| Next Earnings Update | 27 Oct 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Indivior makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 838 | 152 | 461 | 53 |
| 31 Mar 22 | 818 | 166 | 447 | 51 |
| 31 Dec 21 | 791 | 205 | 426 | 52 |
| 30 Sep 21 | 753 | 156 | 383 | 47 |
| 30 Jun 21 | 725 | 139 | 384 | 43 |
| 31 Mar 21 | 674 | 95 | 391 | 39 |
| 31 Dec 20 | 647 | -148 | 427 | 40 |
| 30 Sep 20 | 595 | -190 | 428 | 43 |
| 30 Jun 20 | 634 | -152 | 439 | 47 |
| 31 Mar 20 | 700 | -95 | 427 | 51 |
| 31 Dec 19 | 785 | 134 | 390 | 53 |
| 30 Sep 19 | 889 | 213 | 386 | 53 |
| 30 Jun 19 | 935 | 254 | 404 | 58 |
| 31 Mar 19 | 988 | 248 | 449 | 63 |
| 31 Dec 18 | 1,005 | 275 | 478 | 67 |
| 30 Sep 18 | 1,033 | 106 | 722 | 72 |
| 30 Jun 18 | 1,064 | 67 | 760 | 79 |
| 31 Mar 18 | 1,083 | 71 | 730 | 80 |
| 31 Dec 17 | 1,093 | 58 | 707 | 89 |
| 30 Sep 17 | 1,087 | 281 | 482 | 99 |
| 30 Jun 17 | 1,080 | 81 | 434 | 104 |
| 31 Mar 17 | 1,065 | 65 | 444 | 113 |
| 31 Dec 16 | 1,058 | 35 | 456 | 119 |
| 30 Sep 16 | 1,047 | -6 | 443 | 128 |
| 30 Jun 16 | 1,028 | 191 | 440 | 137 |
| 31 Mar 16 | 1,021 | 201 | 423 | 143 |
| 31 Dec 15 | 1,014 | 228 | 408 | 132 |
Quality Earnings: INDV N has high quality earnings.
Growing Profit Margin: INDV N's current net profit margins (18.1%) are lower than last year (19.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INDV N's earnings have declined by 7.7% per year over the past 5 years.
Accelerating Growth: INDV N's earnings growth over the past year (9.4%) exceeds its 5-year average (-7.7% per year).
Earnings vs Industry: INDV N earnings growth over the past year (9.4%) exceeded the Pharmaceuticals industry 8.1%.
Return on Equity
High ROE: Whilst INDV N's Return on Equity (66.09%) is outstanding, this metric is skewed due to their high level of debt.